Guardant Health And Washington University To Present Study Highlighting Utility Of ctDNA To Address Racial Inequities In Use Of Targeted Therapies And Enrollment In Clinical Trials At 2024 ASCO Meeting
Portfolio Pulse from Benzinga Newsdesk
Guardant Health and Washington University will present a study at the 2024 ASCO meeting highlighting the utility of ctDNA to address racial inequities in the use of targeted therapies and clinical trial enrollment. The study, using the Guardant360® blood test, found that Black patients with PIK3CA mutations in advanced breast cancer were less likely to be enrolled in clinical trials and receive targeted therapy compared to White patients.
June 03, 2024 | 1:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guardant Health's collaboration with Washington University and PMAC to present a study at ASCO 2024 highlights the utility of ctDNA in addressing racial inequities in cancer treatment. This could enhance the company's reputation and adoption of its Guardant360® blood test.
The study's findings and presentation at a major conference like ASCO could boost Guardant Health's reputation and increase the adoption of its Guardant360® blood test, potentially leading to positive short-term stock price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100